AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Anifrolumab Pregnancy Study
Not yet recruiting
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 627
- Registration Number
- NCT07049653
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Not Applicable
Not yet recruiting
- Conditions
- Endometrial CancerMalignant Solid Tumour
- Interventions
- First Posted Date
- 2025-06-30
- Last Posted Date
- 2025-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 700
- Registration Number
- NCT07044336
An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation
Not yet recruiting
- Conditions
- Endometrial Cancer
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT07041606
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
Not yet recruiting
- Conditions
- Bladder Cancer
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT07038928
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
Phase 2
Not yet recruiting
- Conditions
- Mantle-cell Lymphoma
- Interventions
- Drug: Acalabrutinib + R-CHOP standard of careDrug: Acalabrutinib combination with RituximabDrug: Acalabrutinib monotherapy
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT07029737
- Locations
- 🇪🇸
Research Site, Valencia, Spain
Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
Recruiting
- Conditions
- Papillary Renal Cell Carcinoma
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT07024680
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Phase 2
Not yet recruiting
- Conditions
- Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
- Interventions
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT07024706
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
Phase 1
Not yet recruiting
- Conditions
- Chronic Kidney Disease
- Interventions
- Drug: AZD4248Drug: Placebo
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 164
- Registration Number
- NCT07024823
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity/Overweight
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 871
- Registration Number
- NCT07017179
- Locations
- 🇨🇳
Research Site, Shanghai, China
A Study to Assess the Impact of Multiple Doses of AZD6234 on a Single Dose of Combined Oral Contraceptive in Female Participants
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT07013643
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States